TTNP - Titan Pharmaceuticals Inc

TTNP - Titan Pharmaceuticals Inc

https://www.titanpharm.com

Recent News

Powered by Alpha Vantage

Titan Pharmaceuticals Stock Surges 23% After Hours on Stockholder Approval of Three-Way Merger - Titan Pharma ( NASDAQ:TTNP )

Benzinga • 2 weeks, 5 days ago • score: 0.59

Titan Pharmaceuticals, Inc. TTNP closed regular trading at $5.00 per share on Tuesday, before surging 23% to $6.15 in after-hours trading following stockholder approval of a major business combination. Check out the current price of TTNP stock here.

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Titan Pharmaceuticals, Inc. ( TTNP )

Business Insider • 1 month, 2 weeks ago • score: -0.03

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Titan Pharmaceuticals, Inc. ...

Goldman Sachs, M&T Bank And 3 Stocks To Watch Heading Into Monday - Aon ( NYSE:AON ) , Goldman Sachs Group ( NYSE:GS )

Benzinga • 5 months ago • score: 0.40

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects The Goldman Sachs Group, Inc. GS to report quarterly earnings at $12.35 per share on revenue of $14.81 billion before the opening bell, ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapies for the treatment of chronic diseases. The company is headquartered in South San Francisco, California.

52W High

$6.43

52W Low

$3.03

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.42

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.92

EV/Revenue (<3 favorable)

7.04

P/S (TTM) (<3 favorable)

3440.44

P/B (<3 favorable)

2.02

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

49.68%

Institutions (25–75% balanced)

2.83%

Shares Outstanding

1,330,200

Float

823,520

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

3,000

Gross Profit (TTM)

-4,365,000

EPS (TTM)

-2.92

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.83%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—